Accordingly, this study employed both wild-type and mutant p53 GIST models to examine how p53 dysfunction influences GIST biology and to assess its effect on the efficacy of p53-targeted therapies, laying the groundwork for future clinical research. The gene discussed is TP53; the disease is gastrointestinal stromal tumor.